Delta-radiomics increases multicentre reproducibility: a phantom study

Nardone, Valerio; Reginelli, Alfonso; Guida, Cesare; Belfiore, Maria Paola; Biondi, M.; Mormile, M.; Buonamici, F. Banci; Giorgio, Eugenio Di; Spadafora, Marco; Tini, Paolo; Grassi, Roberta; Pirtoli, Luigi; Correale, Pierpaolo; Cappabianca, Salvatore; Grassi, Roberto

doi:10.1007/s12032-020-01359-9

Cited by 61 publications

(41 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DIC is not a disease by itself, but always secondary to an existing disease. It may occur especially after sepsis, various infections, malignancy, obstetric and vascular diseases, severe trauma, toxic and immunological reactions [ 34 , 35 , 36 ]. Severe anaphylaxis and hemolytic transfusion reaction are associated to DIC [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated to the COVID-19 Vaccine Administration

D’Agostino¹,

Caranci

Negro³

et al. 2021

JPM

Self Cite

103

View full text Add to dashboard Cite

Globally, at the time of writing (20 March 2021), 121.759.109 confirmed COVID-19 cases have been reported to the WHO, including 2.690.731 deaths. Globally, on 18 March 2021, a total of 364.184.603 vaccine doses have been administered. In Italy, 3.306.711 confirmed COVID-19 cases with 103.855 deaths have been reported to WHO. In Italy, on 9 March 2021, a total of 6.634.450 vaccine doses have been administered. On 15 March 2021, Italian Medicines Agency (AIFA) decided to temporarily suspend the use of the AstraZeneca COVID-19 vaccine throughout the country as a precaution, pending the rulings of the European Medicines Agency (EMA). This decision was taken in line with similar measures adopted by other European countries due to the death of vaccinated people. On 18 March 2021, EMA’s safety committee concluded its preliminary review about thromboembolic events in people vaccinated with COVID-19 Vaccine AstraZeneca at its extraordinary meeting, confirming the benefits of the vaccine continue to outweigh the risk of side effects, however, the vaccine may be associated with very rare cases of blood clots associated with thrombocytopenia, i.e., low levels of blood platelets with or without bleeding, including rare cases of cerebral venous thrombosis (CVT). We report the case of a 54-year-old woman who developed disseminated intravascular coagulation (DIC) with multi-district thrombosis 12 days after the AstraZeneca COVID-19 vaccine administration. A brain computed tomography (CT) scan showed multiple subacute intra-axial hemorrhages in atypical locations, including the right frontal and the temporal lobes. A plain old balloon angioplasty (POBA) of the right coronary artery was performed, without stent implantation, with restoration of distal flow, but with persistence of extensive thrombosis of the vessel. A successive thorax angio-CT added the findings of multiple contrast filling defects with multi-vessel involvement: at the level of the left upper lobe segmental branches, of left interlobar artery, of the right middle lobe segmental branches and of the right interlobar artery. A brain magnetic resonance imaging (MRI) in the same day showed the presence of an acute basilar thrombosis associated with the superior sagittal sinus thrombosis. An abdomen angio-CT showed filling defects at the level of left portal branch and at the level of right suprahepatic vein. Bilaterally, it was adrenal hemorrhage and blood in the pelvis. An evaluation of coagulation factors did not show genetic alterations so as the nasopharyngeal swab ruled out a COVID-19 infection. The patient died after 5 days of hospitalization in intensive care.

show abstract

Section: Discussionmentioning

confidence: 99%

A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated to the COVID-19 Vaccine Administration

D’Agostino¹,

Caranci

Negro³

et al. 2021

JPM

Self Cite

103

View full text Add to dashboard Cite

show abstract

“…By comparing the differences in patients' longitudinal radiomic data as they progress through treatment, researchers were able to assess treatment response earlier and more reliably than current methods of assessment, such as trending CA-19-9, in pancreatic cancer [14]. A recent study performed by Nardone et al further suggests that the use of radiomics in tracking treatment response is better accomplished by the analysis of delta-radiomics than of a single radiomic dataset [15]. Thus, the use of delta-radiomics creates a unique potential for physicians to adapt treatment plans to patients' treatment response earlier and more accurately than currently possible.…”

Section: Discussionmentioning

confidence: 99%

Radiomics-Based Outcome Prediction for Pancreatic Cancer Following Stereotactic Body Radiotherapy

Parr

Zhang

et al. 2020

Cancers

View full text Add to dashboard Cite

(1) Background: Radiomics use high-throughput mining of medical imaging data to extract unique information and predict tumor behavior. Currently available clinical prediction models poorly predict treatment outcomes in pancreatic adenocarcinoma. Therefore, we used radiomic features of primary pancreatic tumors to develop outcome prediction models and compared them to traditional clinical models. (2) Methods: We extracted and analyzed radiomic data from pre-radiation contrast-enhanced CTs of 74 pancreatic cancer patients undergoing stereotactic body radiotherapy. A panel of over 800 radiomic features was screened to create overall survival and local-regional recurrence prediction models, which were compared to clinical prediction models and models combining radiomic and clinical information. (3) Results: A 6-feature radiomic signature was identified that achieved better overall survival prediction performance than the clinical model (mean concordance index: 0.66 vs. 0.54 on resampled cross-validation test sets), and the combined model improved the performance slightly further to 0.68. Similarly, a 7-feature radiomic signature better predicted recurrence than the clinical model (mean AUC of 0.78 vs. 0.66). (4) Conclusion: Overall survival and recurrence can be better predicted with models based on radiomic features than with those based on clinical features for pancreatic cancer.

show abstract

“…Like blood circulating biomarker changes during treatment could be predictive of the effectiveness of some treatments ( 75 ), the question of radiomics features modification has been studies, called “delta radiomics.” It aims to analyze radiomics features’ evolution through time and treatments based of evaluations obtained from longitudinal scans. Some studies demonstrated that delta radiomics seem to be more robust than radiomics features with the potential of using delta features for early assessment of treatment response and developing tailored therapies ( 76 ). A study focusing on 107 patients with stage III NSCLC ( 77 ) tried to evaluate the impact of radiomics features changes due to radiation therapy and their values at the end of treatment on tumor response.…”

Section: Resultsmentioning

confidence: 99%

The Role of Radiomics in Lung Cancer: From Screening to Treatment and Follow-Up

Ayachy

Giraud

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

PurposeLung cancer represents the first cause of cancer-related death in the world. Radiomics studies arise rapidly in this late decade. The aim of this review is to identify important recent publications to be synthesized into a comprehensive review of the current status of radiomics in lung cancer at each step of the patients’ care.MethodsA literature review was conducted using PubMed/Medline for search of relevant peer-reviewed publications from January 2012 to June 2020ResultsWe identified several studies at each point of patient’s care: detection and classification of lung nodules (n=16), determination of histology and genomic (n=10) and finally treatment outcomes predictions (=23). We reported the methodology of those studies and their results and discuss the limitations and the progress to be made for clinical routine applications.ConclusionPromising perspectives arise from machine learning applications and radiomics based models in lung cancers, yet further data are necessary for their implementation in daily care. Multicentric collaboration and attention to quality and reproductivity of radiomics studies should be further consider.

show abstract

Delta-radiomics increases multicentre reproducibility: a phantom study

Cited by 61 publications

References 40 publications

A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated to the COVID-19 Vaccine Administration

A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated to the COVID-19 Vaccine Administration

Radiomics-Based Outcome Prediction for Pancreatic Cancer Following Stereotactic Body Radiotherapy

The Role of Radiomics in Lung Cancer: From Screening to Treatment and Follow-Up

Contact Info

Product

Resources

About